Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +210,975.57%
#2 Beta Finance Beta Finance +8,979.03%
#3 Tribe Tribe +73.83%
#4 Orochi Network Orochi Network +53.40%
#5 Chainbase Chainbase +40.85%
#6 BabyBoomToken BabyBoomToken +34.25%
#7 Block Street Block Street +31.59%
#8 Chrema Coin Chrema Coin +28.62%
#9 Freysa AI Freysa AI +26.78%
#10 B3 (Base) B3 (Base) +25.98%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Kedudukan dalam Saham #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Harga Saham
$0.00244926
Modal Pasaran
$51.67K
Perubahan (1 hari)
5.88%
Perubahan (1 tahun)
110.15%
Negara
GB
Perdagangan Nuformix plc (NFX)

Kategori

Healthcare
Pendapatan untuk Nuformix plc (NFX)
Pendapatan pada Sep 2025 TTM: $-5.28M
Menurut laporan kewangan terkini Nuformix plc, pendapatan semasa syarikat ialah $-5.28M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $-4.88M, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $-754.56K. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Nuformix plc dari 2014 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-5.28M 494.63%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -387,521.89%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -88,033.93%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -99,160.13%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -40,584.12%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -30,671.66%
AU